PB0955 - Current knowledge on factor V Leiden mutation as a risk factor for recurrent venous thromboembolism: a systematic review and meta-analysis

Monday, July 11, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Co-Author(s)

DE

Daria Eppenberger

Student
University of Bern
Bern, Bern, Switzerland
HN

Henning Nilius

PhD Student & Resident
Department of Clinical Chemistry, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland
Bern, Bern, Switzerland
BA

Betsy Anagnostelis

Researcher
University of Bern
Bern, Bern, Switzerland
CH

Carola A. Huber

Researcher
Helsana health insurance
Zurich, Zurich, Switzerland

Presenting Author(s)

Michael Nagler, MD, PhD, MSc

Deputy Head
Department of Clinical Chemistry, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland
Bern, Bern, Switzerland

Background: Thrombophilia screening is widely done in clinical practice, and it is claimed that the extent of venous thromboembolism (VTE) recurrence risk in patients with common defects is still not fully understood.

Aims: We aimed to summarize all high-quality data of epidemiological studies prospectively observing VTE recurrence in patients with and without heterozygous factor V Leiden (FVL) mutation in various subgroups.

Methods: We searched MEDLINE and EMBASE databases for cohort studies prospectively assessing VTE recurrence in patients with and without FVL (PROSPERO: CRD42021182800). Data were extracted on cohort and study-level. The methodological quality was assessed using the Newcastle-Ottawa Scale (NOS). Relative risks (RR) were calculated overall and in subgroups using a fixed-effects model.

Results: From 30 cohorts, 22 studies were finally included summarizing 13’244 patients. Heterozygous FVL was identified in 2779 individuals (21%). The methodological quality was estimated to be high in 18 studies (82%). The overall RR was 1.4 (95% CI 1.28, 1.55), consistent across subgroups.

Conclusion(s): Pooling all high-quality epidemiological data, the risk of recurrent VTE was increased by 40% in patients with heterozygous FVL mutation. Against the background of established risk factors, the FVL mutation plays only a marginal role in the risk assessment for recurrent VTE.